Top Markets
#1 Islamic Coin Islamic Coin +152.63%
#2 Bitway Bitway +45.44%
#3 Starpower Starpower +37.89%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +37.74%
#5 Pons Pons +33.63%
#6 aelf aelf +26.00%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.55%
#8 SkyAI SkyAI +18.96%
#9 Ocean Protocol Ocean Protocol +16.67%
#10 Decred Decred +14.08%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Classifica tra le azioni #29651
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Prezzo delle azioni
$0.68377137
Ultima sincronizzazione: 2023-05-23
Capitalizzazione di mercato
$20.23M
Variazione (1 giorno)
-0.60%
Variazione (1 anno)
0.00%
Paese
SE
Scambia Medivir AB (publ) (MVIR-B)

Categoria

Healthcare
Rapporto P/S per Medivir AB (publ) (MVIR-B)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Medivir AB (publ), il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Medivir AB (publ) da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR